BIOMAT Database Logo BIOMAT Database Logo

Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide. 2012

Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008998 Monoclonal Gammopathy of Undetermined Significance Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia. Benign Monoclonal Gammopathies,Monoclonal Gammapathy of Undetermined Significance,Monoclonal Gammopathies, Benign,Monoclonal Gammapathies, Benign,Benign Monoclonal Gammapathies,Benign Monoclonal Gammapathy,Benign Monoclonal Gammopathy,Monoclonal Gammapathy, Benign,Monoclonal Gammopathy, Benign
D003449 Cryoglobulinemia A condition characterized by the presence of abnormal quantities of CRYOGLOBULINS in the blood. Upon cold exposure, these abnormal proteins precipitate into the microvasculature leading to restricted blood flow in the exposed areas. Cryoglobulinemias
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000744 Anemia, Hemolytic, Autoimmune Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS. Anemia, Hemolytic, Idiopathic Acquired,Autoimmune Haemolytic Anaemia,Autoimmune Hemolytic Anemia,Cold Agglutinin Disease,Hemolytic Anemia, Autoimmune,Acquired Autoimmune Hemolytic Anemia,Anemia, Hemolytic, Cold Antibody,Cold Antibody Disease,Cold Antibody Hemolytic Anemia,Idiopathic Autoimmune Hemolytic Anemia,Agglutinin Disease, Cold,Anaemia, Autoimmune Haemolytic,Anemia, Autoimmune Hemolytic,Autoimmune Haemolytic Anaemias,Autoimmune Hemolytic Anemias,Cold Agglutinin Diseases,Cold Antibody Diseases,Haemolytic Anaemia, Autoimmune
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
[Successful treatment with rituximab in two cases of IgM-monoclonal gammopathy of undetermined significance (MGUS) neuropathy].
April 2012, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
Lymphoproliferative disease with monoclonal IgM lambda gammopathy and cold agglutinin.
October 1979, Australian and New Zealand journal of medicine,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
[Chronic cold agglutinin disease: significance as monoclonal gammopathy].
January 1972, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.
November 1996, Neurology,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
Refractory immune thrombocytopenic purpura associated with IgM monoclonal gammopathy of undetermined significance: Successful treatment with tirabrutinib plus conventional therapies.
May 2022, EJHaem,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
IgAλ monoclonal gammopathy of undetermined significance (MGUS) associated with primary selective IgM deficiency.
January 2019, American journal of clinical and experimental immunology,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
April 2003, Seminars in oncology,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
Successful Treatment of Concomitant Pleural Mucosa-Associated Lymphoid Tissue Lymphoma and Monoclonal Gammopathy of Undetermined Significance with Lenalidomide, Rituximab, and Dexamethasone.
January 2022, Case reports in hematology,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
Dense deposit disease associated with monoclonal gammopathy of undetermined significance.
November 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Joyeeta Bhattacharyya, and Keichiro Mihara, and Yoshihiro Takihara, and Akiro Kimura
IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia.
March 2009, Clinical lymphoma & myeloma,
Copied contents to your clipboard!